Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences Authority of Singapore to initiate a Phase I clinical study for its radiopharmaceutical candidate, 68Ga-LNC1007. This diagnostic agent targets fibroblast activating protein (FAP) and integrin αvβ3, and is being developed to aid in the treatment of FAP and αvβ3-positive solid tumors.
Preclinical studies and investigator-initiated trials have demonstrated that 68Ga-LNC1007 significantly enhances tumor uptake, improves targeting efficiency, and optimizes pharmacokinetics, all while maintaining a favorable safety profile. The compound is anticipated to provide superior tumor imaging capabilities in various cancers, including lung, breast, renal cell, esophageal, pancreatic, and ovarian cancers. As such, 68Ga-LNC1007 is expected to play a crucial role in the diagnosis of multiple solid tumor types in the future.- Flcube.com
